Severe infections raise dementia risk in large Finnish study

A study of over 375,000 Finns has linked hospital treatment for severe infections like cystitis and pneumonia to a higher risk of developing dementia within five to six years. Researchers identified 29 conditions associated with at least a 20 percent increased risk, with infections playing a key role. The findings suggest that preventing such infections could help modify dementia risk.

Researchers led by Pyry Sipilä at the University of Helsinki analyzed health records of 62,555 people aged 65 or older who received a dementia diagnosis between 2017 and 2020. They compared these individuals to 312,772 matched controls without dementia, tracking diagnoses and hospitalizations over the prior two decades, including matching for age, sex, education, and marital status. The study, published in PLOS Medicine (DOI: 10.1371/journal.pmed.1004688), found 29 conditions linked to at least a 20 percent higher dementia risk about five to six years later. Most were non-infectious, affecting the heart or brain, but cystitis—a bacterial urinary tract infection—and unspecified bacterial infections stood out. Further analysis showed these infections drove much of the elevated risk. Sipilä noted that infection-related inflammation might breach the blood-brain barrier, causing damage, and pointed to emerging evidence that vaccines for shingles and flu could lower dementia odds. For early-onset dementia before age 65, Parkinson's disease and head trauma posed the highest risks, but infections such as gastroenteritis, infectious or unspecified colitis, pneumonia, tooth decay, and unspecified bacterial infections roughly doubled the risk. Kuan-Ching Wu at Emory University, who was not involved, said the results suggest dementia risk may be partially modifiable through infection prevention, like hydration and prompt UTI treatment in older adults, where symptoms can mimic confusion. Gill Livingston at University College London called it a high-quality study with biological plausibility supporting a potential causal link. Sipilä cautioned that correlations do not prove causation and called for intervention trials to test prevention strategies.

Awọn iroyin ti o ni ibatan

Lab scene illustrating breakthrough Alzheimer's drug candidates: Zostavax vaccine, sildenafil (Viagra), riluzole with brain model and expert panel.
Àwòrán tí AI ṣe

Experts flag shingles vaccine, sildenafil and riluzole as leading Alzheimer’s repurposing candidates

Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo

A University of Exeter-led study funded by Alzheimer’s Society has identified three already-approved medicines—the shingles vaccine Zostavax, sildenafil (Viagra) and riluzole—as top “priority” candidates to be tested in clinical trials for Alzheimer’s disease, after a structured review of 80 existing drugs by an international expert panel.

A study involving 73 people with mild cognitive impairment or early dementia found that tailored treatment plans targeting nutritional deficiencies, infections and other factors led to significant cognitive improvements after nine months. Participants in the intervention group saw their overall cognitive scores rise by 13.7 points, while the control group declined by 4.5 points. The approach combines medical interventions with lifestyle changes like diet, exercise and cognitive training.

Ti AI ṣe iroyin

Researchers have discovered that Chlamydia pneumoniae, a bacterium commonly causing pneumonia and sinus infections, may contribute to Alzheimer's disease by invading the retina and brain. The study found higher levels of the bacterium in Alzheimer's patients, particularly those with the APOE4 gene variant, associated with greater cognitive decline. This suggests potential new treatment avenues targeting infection and inflammation.

A team of researchers led by Professor Yan-Jiang Wang has published a review arguing that Alzheimer's disease requires integrated treatments targeting multiple factors, not single causes. New drugs like lecanemab and donanemab offer modest benefits by slowing decline, but fall short of reversal. The paper, in Science China Life Sciences, emphasizes genetics, aging, and systemic health alongside amyloid-beta and tau proteins.

Ti AI ṣe iroyin

A new study reveals that people with severe obesity face a significantly higher risk of severe or fatal infections. Drawing on data from over 540,000 individuals in the UK and Finland, the risk for grade 3 obesity is three times higher than for those of normal weight. Researchers warn of rising global obesity rates.

Ojú-ìwé yìí nlo kuki

A nlo kuki fun itupalẹ lati mu ilọsiwaju wa. Ka ìlànà àṣírí wa fun alaye siwaju sii.
Kọ